CCL2 and prostate carcinoma: Interestingly, other studies indicated ASC-J9® could also suppress prostate cancer progression via an AR-independent mechanism involving the suppression of STAT3-CCL2 signaling [11], which could explain why ASC-J9® could also suppress both BCa AR-positive TCC-SUP cells and AR-negative J82 cells.